- Previous Close
7.52 - Open
7.50 - Bid 7.15 x 800
- Ask 7.64 x 800
- Day's Range
7.28 - 7.56 - 52 Week Range
5.95 - 20.75 - Volume
452,185 - Avg. Volume
1,047,757 - Market Cap (intraday)
372.335M - Beta (5Y Monthly) 1.13
- PE Ratio (TTM)
-- - EPS (TTM)
-2.09 - Earnings Date Feb 12, 2025 - Feb 17, 2025
- Forward Dividend & Yield 0.24 (3.20%)
- Ex-Dividend Date Nov 29, 2024
- 1y Target Est
8.25
Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO; and nutricentials skin care products. The company also provides wellness products, such as LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
www.nuskin.com3,700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NUS
View MorePerformance Overview: NUS
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NUS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NUS
View MoreValuation Measures
Market Cap
372.34M
Enterprise Value
636.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.21
Price/Book (mrq)
0.53
Enterprise Value/Revenue
0.36
Enterprise Value/EBITDA
80.99
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.81%
Return on Assets (ttm)
5.54%
Return on Equity (ttm)
-13.50%
Revenue (ttm)
1.78B
Net Income Avi to Common (ttm)
-103.21M
Diluted EPS (ttm)
-2.09
Balance Sheet and Cash Flow
Total Cash (mrq)
244.09M
Total Debt/Equity (mrq)
75.09%
Levered Free Cash Flow (ttm)
131.05M